{"id":"clobetasone-butyrate-0-05-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation or burning"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobetasone butyrate is a Class III (mild-to-moderate potency) topical corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators and reduced immune cell infiltration. This results in reduced erythema, pruritus, and other signs of skin inflammation. The 0.05% cream formulation is designed for topical application to affected skin areas.","oneSentence":"Clobetasone butyrate is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:21.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis)"}]},"trialDetails":[{"nctId":"NCT03345914","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-17","conditions":"Dermatitis, Atopic","enrollment":367},{"nctId":"NCT01567995","phase":"PHASE3","title":"Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-28","conditions":"Eczema","enrollment":240},{"nctId":"NCT01452997","phase":"PHASE4","title":"Evaluation of Anti-inflammatories in the Reduction of Bite Reactions","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2012-11","conditions":"Mosquito Bite","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Clobetasone Butyrate 0.05% Cream","genericName":"Clobetasone Butyrate 0.05% Cream","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobetasone butyrate is a topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, dermatitis, psoriasis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}